Role of AT1-receptor Blockers in Insulin-induced Vasodilation.

Maastricht University Medical Centre (MUMC)

Status: Unknown

Conditions: Hypertension; Insulin Resistance; Microcirculation

Treatments: Drug: Placebo; Drug: Felodipine; Drug: Irbesartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00742066

MEC 07-2-115

Details and patient eligibility

About

In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2. Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular effects in normotensive control subjects?

Enrollment: 32 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

hypertensive subjects:

1. 18-60 years
2. Caucasian
3. untreated hypertension >140/90mmHg.

normotensive subjects:

1. 18-60 years
2. Caucasian
3. Blood pressure <140/90 mmHg.

Exclusion criteria

1. Obesity (BMI>27kg/m2)
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use >4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
7. Pregnancy
8. Wearing contact lenses

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

32 participants in 3 patient groups, including a placebo group

I

Experimental group

Description:

Irbesartan

Treatment:

Drug: Irbesartan

II

Active Comparator group

Description:

Felodipine

Treatment:

Drug: Felodipine

III

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo